Member Info for PeterS23

Oasis

1 CF has stated in previous presentations that shareholders in ORPH will be given a share on a 1:1 ratio in Imutex if it is listed on NASDAQ.

2 No further investment needed, but you need to be holding the ORPH shares when the announcement is made. That will be the cut off date so to speak.

3 The value will be given in an announcement by ORPH on the day it is announced. CF’s guidance on this is that ORPH’s value in Imutex is circa £150m which equates to about £0.22p per share.

All IMO. DYOR

Interestking - I’m about to make you happy.

Firstly, I’ve posted 20 times on this BB, starting 4th October. You must be unaware that to check someone’s posting history, you only have to click on the name of the poster and a hyperlink will take you through all that persons posts. Of course you mustn’t have realised that otherwise you’d have spent 20 seconds checking first before posting inaccurate information about me. Ditto the 8 people who have so far liked your post.
Secondly, “he sounds like a perfectly balanced argument that I would employ for £1/6d an hour”. Que? Did this argument have to pass an interview to get the job?

Rossannan - I too was unimpressed by the comments from James Smith, Director at BPC. If he’d said “the board of BPC and it’s Directors have considered the legal challenge and deem it completely without merit” then I’d feel far more comfortable that the challenge will be dismissed. Obviously he will have had dialogue with the other board members in the last few days, and instead he’s complained that any delay etc with be economically damaging to the Bahamians (taken from ‘The Tribune’ article I found in a google search). I’ve stated on here that the Judge in this case will assess it on its legal compliance, not economic considerations. Still hoping though that the challenge has no merits, but from what I’ve read I just don’t share some other investors total confidence at present.

Autonomy1, I agree with your comments. I’m only recently invested here, unlike you. I’ve been on the receiving end of a spurious legal defence claim and you’re right in stating that it causes delay whilst’s it’s dealt with by the court. Given BPC have not issued an RNS as yet in response to all this, then I suspect BPC are actively reviewing their application, and may have found it didn’t jump 100% all the hurdles it was meant to. Ergo, there is a problem to be addressed. As I’ve said before, a QC has submitted this legal challenge, and I can’t see why he’d do so without some (even a slender chance) of success in delaying matters. I’m holding though, as I think any delay will be relatively small (3 to 6 months) which isn’t a concern to me given the upside that will come our way. IMO . GLA

Thanks for the responses on this. It has further clarified to me what I think we already know. i.e. we’re now undervalued on our core assets alone when factoring in the profitability that’s now been achieved. Any value delivered by Imutex and wearables will be a thick slice of icing on the cake (and may be thicker than the cake!) IMO. DYOR. GLA

www.ergomedplc.com

Morning all,

I posted the following in the early hours of Thursday morning, and then a few hours later an RNS was issued, and hence it looks like it went perhaps understandably went under the radar of most on this board. I therefore decided to re-post it below after the furore of CF’s presentation has died down, and also it may give us all something to chew over in lockdown. I’m not invested in ERGO, and not considering investing there (the train has left the station there I think) but I am heavily invested in ORPH.

Thursdays post below:

I received an email today recommending I look at potentially investing in an AIM Company called Ergomed (ERGO), who ply there trade in the same area as ORPH, i.e. ‘Health Care’ as the FTSE industry classification.

Doing some comparisons with ORPH throws up some interesting findings;

ERGO’s last accounts to 31-12-2019 show the had an annual turnover of £68m and made a profit of £5m. The previous years of 2018 & 2017, they made losses of £10m and £4m on turnover of £54m & £48m respectively. This profile is I think quite similar to ORPH’s (as CF has stated ORPH now achieving profitability)

The share price essentially flatlined from 2015 to December 2018, finishing at 165p.

However since it reached profitability in 2019, the share price has risen from 165p to today’s 820p. It’s market cap is now £400m, and it has a price earning ratio of 66. (However ERGO has posted interim results to 30-06-20 which show a 40% increase in half year profits, and these are not reflected in the P/E ratio of 66)

ORPH has now reached profitability and I’m therefore confident it’s share price will continue its ascent, though I don’t know enough about ERGO to be confident that ORPH can be directly compared, or even loosely compared to ERGO and it’s market cap? (although I think it can and hence I’ve posted this comparison)

Perhaps someone on this board with more knowledge of the sector can assist in this?

TIA

Thanks laallee for that article.

It clearly states that the activists “claim that the company’s environmental impact statement (eis) has not been completed, given that it had to make amendments when it changed the ship it intends to use for drilling”

Anyone on here have any industry experience/knowledge in such matters? i.e. is the eis incomplete if merely the ship being employed is a different ship to that named? Seems harsh, but is it incomplete? TIA

Nice work Wally. Thanks

I received an email today recommending I look at potentially investing in an AIM Company called Ergomed (ERGO), who ply there trade in the same area as ORPH, i.e. ‘Health Care’ as the FTSE industry classification.

Doing some comparisons with ORPH throws up some interesting findings;

ERGO’s last accounts to 31-12-2019 show the had an annual turnover of £68m and made a profit of £5m. The previous years of 2018 & 2017, they made losses of £10m and £4m on turnover of £54m & £48m respectively.

The share price essentially flatlined from 2015 to December 2018, finishing at 165p.

However since it reached profitability in 2019, the share price has risen from 165p to today’s 820p. It’s market cap is now £400m, and it has a price earning ratio of 66. (However ERGO has posted interim results to 30-06-20 which show a 40% increase in half year profits, and these are not reflected in the P/E ratio of 66)

ORPH has now reached profitability and I’m therefore confident it’s share price will continue its ascent, though I don’t know enough about ERGO to be confident that ORPH can be directly compared, or even loosely compared to ERGO and it’s market cap? (although I think it can and hence I’ve posted this comparison)

Perhaps someone on this board with more knowledge of the sector can assist in this?

TIA

Food for thought Bronx. Never say never and all that.

Generally agree with that Markshares and in hindsight it would be have been better if he expressed his projections in those terms. The point I’m trying to make is that I believe Imutex would have been sorted by Xmas had he not had to deal with wearables, and the UK Govt contract, and the expansion of the quarantine facilities. So I don’t think he was being over ambitious or unrealistic when he made that Xmas claim. Events overtook him, causing the delay. IMO

Bronx, I think using the term BS is harsh. Yes, it seems CF might not hit the exact dates he’s forecast previously, but we won’t have to wait too long after. Moreover, he’s had to juggle a lot of plates in the last six months, and has delivered in spades, doubling the share price in that period. With Apple & Co appearing on the horizon within that time period, it should be no surprise there’s been some slippage in other areas (Imutex) whilst he deals firstly with wearables. As long as he gets the right deals for us shareholders in the medium and long term, this should always take precedence over short term gains. IMO

This gets to £1 billion and I’ll vote for CF as our next Prime Minister (ok, I know he’s Irish and you don’t actually vote for a Prime Minister, but you get the drift)

Thinks you missed an ‘e’ there Swap!

Excellent post Trader 3

Big thanks to all who’ve took the time to respond to my original query. As I’ve stated I’m heavily invested here and was already 90% confident that CF will deliver on his promises to shareholders. I therefore totally agree with Wondergoals about investing on future prospects and will continue to hold, and probably add when I can do so, although ORPH now accounts for some 85% of my portfolio. GLA

Tullaghan, if you read my original post on this subject all should become clear, and you’ll see that nobody has left this asset off as a matter on convenience. TIA

PS - thanks to all of you who responded in a helpful manner to to my earlier query.

Strict - last post was for Barwickman - obviously